When Penny Stocks Can Become Compelling: A Long-Term Buy With CYDY
April 03, 2025 at 21:19 PM EDT
CytoDyn represents a speculative bet on a once-celebrated drug that is now steadily rebuilding its case. If leronlimab can fulfill its early promise in metastatic triple-negative breast cancer, the rewards could be substantial.